PDCD1 and melanoma: Perhaps unsurprisingly, the combination of anti-CTLA-4 and anti-PD-1 treatments resulted in longer overall survival in patients with advanced melanoma, renal-cell carcinoma, and DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer [102,103,104].